---
title: CDMO Daily News — September 3, 2026
slug: daily-news-2026-09-03-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 3 CDMO daily: Genprex Taps Andelyn Biosciences for AAV Diabetes Gene Therapy Scale-Up; Lifecore Biomedical Wins Commercial Injectable Transfer;…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-03-cdmo
published_at: 2026-09-03T23:59:52.835Z
last_updated: 2026-09-04T00:00:30.083Z
---

### Genprex Taps [Andelyn Biosciences](/companies/andelynbio) for AAV Diabetes Gene Therapy Scale-Up
- Genprex selected [Andelyn Biosciences](/companies/andelynbio) to support manufacturing scale-up for a dual-indication (type 1 and type 2) diabetes gene therapy using AAV vector delivery to the pancreas.
- Andelyn will provide process optimization, IND-enabling studies, cGMP clinical-stage manufacturing, and analytical/potency assay development via its Curator cell and gene therapy platform.

**Operational Impact**

Andelyn's engagement to deliver IND-enabling and cGMP manufacturing for an AAV gene therapy expands its cell and gene therapy workload and demonstrates capability in complex pancreatic-directed therapies ahead of clinical advancement.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/genprex-selects-andelyn-biosciences-to-scale-manufacturing-for-diabetes-gene-therapy-program)*

---

### [Lifecore](/companies/lifecore) Biomedical Wins Commercial Injectable Transfer; Seventh Late-Stage Program in 2026
- [Lifecore](/companies/lifecore) signed a technical transfer agreement for a commercially marketed injectable drug with unique formulation and manufacturing complexity.
- The program marks Lifecore's seventh late-stage commercial addition and 11th pipeline program in 2026, with commercial revenues expected in 2028.
- Lifecore's late-stage pipeline now contains 13 programs projected to generate commercial revenues by end of 2028.

**Operational Impact**

[Lifecore](/companies/lifecore)'s seventh late-stage commercial program adds injectable manufacturing capacity and revenue visibility through 2028, demonstrating successful execution of its commercial pipeline-building strategy and expanding customer relationships in complex injectables.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/lifecore-biomedical-signs-agreement-for-commercial-injectable-drug-transfer)*

## References

1. [Contract Pharma Breaking News RSS — Genprex Taps Andelyn Biosciences for AAV Diabetes Gene Therapy Scale-Up](https://www.contractpharma.com/breaking-news/genprex-selects-andelyn-biosciences-to-scale-manufacturing-for-diabetes-gene-therapy-program)
2. [PharmaSource RSS — Lifecore Biomedical Wins Commercial Injectable Transfer; Seventh Late-Stage Program in 2026](https://pharmasource.global/content/news/cdmo-news/lifecore-biomedical-signs-agreement-for-commercial-injectable-drug-transfer)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-03-cdmo